Cefmetazole |
 |
|
| AHFS/Drugs.com | International Drug Names |
|---|
| MedlinePlus | a601206 |
|---|
| ATC code | |
|---|
|
(6R,7S)-7-(2-(cyanomethylthio)acetamido)-7-methoxy-3-((1-methyl-1H-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| CompTox Dashboard (EPA) | |
|---|
| ECHA InfoCard | 100.054.877 |
|---|
|
| Formula | C15H17N7O5S3 |
|---|
| Molar mass | 471.53 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)CSCC#N)CSc3nnnn3C)C(=O)O
|
InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1 YKey:SNBUBQHDYVFSQF-HIFRSBDPSA-N Y
|
N Y (what is this?) (verify) |
Cefmetazole is a cephamycin antibiotic, usually grouped with the second-generation cephalosporins.
Adverse effects
The chemical structure of cefmetazole, like that of several other cephalosporins, contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram, due to inhibition of aldehyde dehydrogenase.[1]
Spectrum of bacterial susceptibility
Cefmetazole is a broad-spectrum cephalosporin antimicrobial and has been effective in treating bacteria responsible for causing urinary tract and skin infections. The following represents MIC susceptibility data for a few medically significant microorganisms.
- Bacteroides fragilis: 0.06 - >256 μg/ml
- Clostridioides difficile: 8 - >128 μg/ml
- Staphylococcus aureus: 0.5 - 256 μg/ml (includes MRSA)[2]
References
Antibacterials active on the cell wall and envelope (J01C-J01D) |
|---|
β-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) | | Penicillins (Penams) | Narrow spectrum | β-lactamase sensitive (1st generation) | |
|---|
β-lactamase resistant (2nd generation) | |
|---|
|
|---|
Extended spectrum | | Aminopenicillins (3rd generation) | |
|---|
| Carboxypenicillins (4th generation) | |
|---|
| Ureidopenicillins (4th generation) | |
|---|
| Other | |
|---|
|
|---|
|
|---|
| Carbapenems / Penems |
- Carbapenems (Ertapenem
- Antipseudomonal (Doripenem
- Imipenem
- Meropenem)
- Biapenem‡
- Panipenem)
- Penems (Faropenem
- Ritipenem§
- Sulopenem)
|
|---|
Cephems Cephalosporins Cephamycins Carbacephems | | 1st generation | |
|---|
| 2nd generation | |
|---|
| 3rd generation | |
|---|
| 4th generation |
- Cefepime
- Cefozopran‡
- Cefpirome
- Cefquinome‡
|
|---|
| 5th generation |
- Ceftaroline fosamil
- Ceftolozane
- Ceftobiprole
|
|---|
| Siderophore | |
|---|
| Veterinary |
- Ceftiofur
- Cefquinome
- Cefovecin
|
|---|
|
|---|
| Monobactams |
- Aztreonam
- Tigemonam‡
- Carumonam‡
- Nocardicin A‡
|
|---|
| β-lactamase inhibitors |
- Penam (Sulbactam
- Tazobactam
- Enmetazobactam)
- Clavam (Clavulanic acid)
- non-β-lactam (Avibactam
- Durlobactam
- Relebactam
- Taniborbactam
- Vaborbactam)
|
|---|
| Combinations |
- Amoxicillin/clavulanic acid#
- Ampicillin/flucloxacillin
- Ampicillin/sulbactam (Sultamicillin)
- Aztreonam/avibactam
- Benzathine benzylpenicillin/procaine benzylpenicillin
- Cefepime/enmetazobactam
- Cefepime/sulbactam
- Cefoperazone/sulbactam
- Ceftazidime/avibactam
- Ceftolozane/tazobactam
- Imipenem/cilastatin#
- Imipenem/cilastatin/relebactam
- Meropenem/vaborbactam
- Panipenem/betamipron
- Piperacillin/tazobactam
- Sulbactam/durlobactam
- Sulopenem/probenecid
- Ticarcillin/clavulanic acid
|
|---|
|
|---|
| Polypeptides | | Lipopeptides |
- Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
- Surfactin
|
|---|
| Other |
- Inhibits PG elongation and crosslinking: Ramoplanin§
|
|---|
|
|---|
| Intracellular |
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
- DADAL/AR inhibitors
- bactoprenol inhibitors
|
|---|
| Other |
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|